AstraZeneca PLC
[AZN]
NYSE
MVPro™ Score: 63/100
Last Earnings: 06 Nov 2025
[AZN]
NYSE
MVPro™ Score: 63/100
Last Earnings: 06 Nov 2025
Powered by AI
| Capitalization (mln USD) | 235,814 |
| Revenue (mln USD) | 14,457 |
| EBITDA (mln USD) | 4,897 |
| Net Income (mln USD) | 2,450 |
| Net Margin | 16.95% |
| EPS Ratio (TTM, USD) | 2.66 |
| P/E Ratio (TTM) | 28.41 |
| P/S Ratio (TTM) | 3.83 |
| D/E Ratio | 1.51 |
| EV/EBITDA (TTM) | 15.25 |
| CAPEX (Q/Q) | 98.45% |
| Dividend Yield | 1.98% |
Revenue, EBITDA & Net Income
Company Overview
AstraZeneca PLC is a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom, with origins in the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group. Since then, the firm has become one of the world’s leading pharmaceutical players, building a strong reputation for innovation and global reach. Its history shows a consistent focus on advancing healthcare through pioneering research and development.
The company’s core activities include the discovery, development, and commercialisation of prescription medicines, with emphasis on oncology, cardiovascular, renal, respiratory, and rare diseases. Its recognised products include Tagrisso for lung cancer, Symbicort for asthma, and treatments for metabolic and immunological conditions. AstraZeneca also invests in biotechnology, vaccines, and next-generation therapies to reinforce its competitive position.
The group is currently led by Chief Executive Officer Pascal Soriot, who has guided its strategy since 2012. AstraZeneca operates across more than 100 countries, with especially strong positions in Europe, North America, and emerging markets such as China. Its mission is to push the boundaries of science to deliver life-changing medicines, and its ESG commitments are demonstrated through sustainability initiatives, equitable access to healthcare, and responsible business practices supporting long-term growth.
🟡 P/E (Price to Earnings, TTM)
Price-to-earnings (P/E) ratio for the most recent quarter is 26.1, compared to 29.3 in the previous quarter, with a longer-term trend value of 42.9. This decline in the P/E ratio may indicate a shift in market sentiment, where investors are placing a lower premium on future earnings growth. A falling P/E ratio could be driven by slowing revenue growth, increased risk perception, or improved earnings performance that is outpacing stock price growth.
P/E Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (TTM)
P/E Ratio
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟢 EPS (Earnings Per Share, TTM)
AstraZeneca's earnings per share (EPS) for the most recent quarter is 2.66 USD (+6.9%), compared to 2.49 USD in the previous quarter, with a longer-term trend value of 3.95 USD. This quarterly increase in EPS suggests improved profitability and operational efficiency.
EPS
Source: MarketVectors.Pro, AstraZeneca Financial Reports (TTM, USD)
EPS
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 P/B (Price to Book)
Price-to-book (P/B) ratio for the most recent quarter stands at 4.83 (-12.8%), compared to 5.54 in the previous quarter, with a long-term trend value of 3.91. This decline in the P/B ratio may indicate a more conservative market stance on the company’s asset valuation, potentially influenced by shifting investor sentiment, changes in financial fundamentals, or broader economic conditions.
P/B Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports
P/B Ratio
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 EBIT
EBIT for AstraZeneca in the most recent quarter is 3,508 million USD, compared to 3,674 million USD in the previous quarter, with a long-term trend value of 2,093 million USD. This decline may indicate increased costs, lower revenue, or market challenges impacting profitability, requiring strategic adjustments.
EBIT
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
EBIT
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Risk Assessment
This assessment outlines the key risks that may influence the company’s performance and long-term stability.
Market Risk
AstraZeneca operates in a highly competitive pharmaceutical market where innovation cycles and patent expiries affect revenue streams. Demand is influenced by global healthcare budgets, pricing pressures, and shifting demographics. Economic downturns or reduced government spending on healthcare could also impact product sales.
Financial Risk
Although AstraZeneca maintains a solid financial position, currency fluctuations across its global operations pose risks to profitability. High research and development costs, combined with long product development cycles, create pressure on cash flow and margins. Dependence on a limited number of blockbuster drugs increases vulnerability when exclusivity periods expire.
Operational Risk
Complex supply chains across multiple geographies expose the firm to risks of disruption in raw materials and logistics. Any manufacturing or quality control failures could lead to recalls, reputational damage, or delays in product delivery. The success of its research pipeline is uncertain, with high attrition rates in drug development.
Regulatory Risk
AstraZeneca faces extensive regulation across all markets, particularly regarding drug approvals, safety monitoring, and compliance standards. Delays in securing approvals or adverse findings from regulators could materially impact financial performance. Increasing expectations around ESG disclosure and equitable access to medicines add further compliance challenges.
Overall Risk Assessment
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Piotroski F-Score Analysis
Piotroski F-Score analysis is a robust methodology designed to assess the financial strength and operational efficiency of companies, providing valuable insights for investment decision-making.
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
| Previous TTM | Current TTM | Score | |
| Net Income | 6,440 | 8,299 | 1 |
| ROA | 6.38% | 7.76% | 1 |
| Net Operating Cash Flow | -871 | 342 | 1 |
| OCF > Net Income | 2,483 | 5,090 | 1 |
| Long-Term Debt | 99,074 | 106,799 | 0 |
| Current Ratio | 0.89 | 0.86 | 0 |
| New Shares Issued (mln) | 3,120 | 3,118 | 1 |
| Gross Margin | 82.08% | 81.38% | 0 |
| Total Asset Turnover Ratio | 0.49 | 0.53 | 1 |
| Piotroski F-Score | 6/9 |
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Altman Z-Score Analysis
Altman Z-Score is a widely recognised financial metric used to evaluate the risk of bankruptcy for companies. It is particularly relevant for assessing the creditworthiness of manufacturing and industrial companies but has also been adapted for other industries.
Source: MarketVectors.Pro, AstraZeneca Financial Reports
| Q2 25 | |||
| Altman Z-Score (TTM) | 2.89 | ||
| 0 | Distress | 1.8 | Grey | 2.99 | Safe | 4 |
Source: MarketVectors.Pro, AstraZeneca Financial Reports
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Key Assets Components
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
As of last quarter the company reported total assets of 112,422 million USD, representing an increase of 7.7% compared to the previous year the same quarter 104,340 million USD. The largest contributor to this change in current assets was Receivables, which grew by 20.2% to 15,169 million USD from 12,622 million USD.
Assets
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
| Q2 24 | Q2 25 | Change (%) | |
| Cash & Short-Term Inv | 7,104 | 7,203 | 1.39% |
| Inventory | 5,667 | 6,467 | 14.12% |
| Receivables | 12,622 | 15,169 | 20.18% |
| Total Current Assets | 25,393 | 28,939 | 13.96% |
| Property and Equipment | 9,630 | 11,637 | 20.84% |
| Goodwill, Intangibles | 60,486 | 59,147 | -2.21% |
| Other Long-Term Assets | 0 | 0 | 0.00% |
| Total Assets | 104,340 | 112,422 | 7.75% |
Assets
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🔴 Key Liabilities & Equity
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Total current liabilities increased by 17.4%, indicating a potential growth in operational activities. This change may affect the company's ability to manage its working capital efficiently. Long-term debt decreased by 9.2%, suggesting a reduction in financial leverage. This shift could have implications for the AstraZeneca's financing costs and overall debt strategy.
Liabilities & Equity
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
| Q2 24 | Q2 25 | Change (%) | |
| Accounts Payable | 20,463 | 23,986 | 17.22% |
| Accrued Expenses, Other | 2,219 | 2,219 | 0.00% |
| Total Current Liabilities | 28,566 | 33,536 | 17.40% |
| Long-term Lease | 1,241 | 1,633 | 31.59% |
| Long-term Debt | 27,225 | 24,714 | -9.22% |
| Total Liabilities | 64,742 | 67,612 | 4.43% |
| Shareholders’ Equity | 39,598 | 44,810 | 13.16% |
Liabilities & Equity
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟢 Income Statement Analysis
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
As of Q2 25, AstraZeneca reported a revenue of 14,457 million USD, marking an increase of 11.7% compared to the previous year to 12,938 million USD. Operating expenses rose to 8,476 million USD, increasing by 1.2% year-on-year from 8,378 million USD.
Revenue & Net Income
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
| Q2 24 | Q2 25 | Change (%) | |
| Revenue | 12,938 | 14,457 | 11.74% |
| Operating Expenses | 8,378 | 8,476 | 1.17% |
| Operating Income | 2,746 | 3,508 | 27.75% |
| Net Income | 1,927 | 2,450 | 27.14% |
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
Revenue & Net Income
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Cash Flow Analysis
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
The company’s cash flow performance over the year demonstrates varied trends across key categories. Net operating cash flows increased by 9.8% from 3,085 million USD to 3,386 million USD, reflecting stronger cash generation from core business activities. Net investing cash flows increased by 26.6% from -2,872 million USD to -2,108 million USD, indicating reduced expenditure on investments, potentially related to strategic initiatives.
Operating Cash Flow
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
| Q2 24 | Q2 25 | Change (%) | |
| Net Operating Cash Flows | 3,085 | 3,386 | 9.76% |
| Net Investing Cash Flows | -2,872 | -2,108 | 26.60% |
| Net Financing Cash Flows | -1,222 | 518 | 142.39% |
| Net Cash Flow, Equivalents | -1,009 | 1,796 | 278.00% |
Operating Cash Flow
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 EBITDA
AstraZeneca's EBITDA for the most recent quarter is 4,897 milion USD (-1.2%), compared to 4,958 milion USD in the previous quarter, with a long-term trend value of 4,645 milion USD. This decline in EBITDA may suggest increased operating costs, lower revenue generation, or other external factors affecting profitability.
EBITDA
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
EBITDA
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Net Income
Net income for the most recent quarter is 2,450 milion USD (-16.1%), compared to 2,921 milion USD in the previous quarter, with a long-term trend value of 1,868 milion USD. This decline in net income may indicate increased operational costs, lower revenue generation, or external market challenges affecting profitability.
Net Income
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Net Income
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 ROE (Return on Equity, %) ★ Buffett's Key Metric
AstraZeneca's return on equity (ROE) for the most recent quarter is 18.5%, compared to 18.9% in the previous quarter, with a long-term trend value of 26.7%. This decline in ROE may indicate reduced profitability, increased equity base, or other financial challenges affecting the company's return on investment.
ROE Indicator
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
ROE Indicator
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟢 ROA (Return on Assets, %)
Return on assets (ROA) for the most recent quarter is 7.4%, compared to 7.3% in the previous quarter, with a long-term trend value of 10.9%. This increase in ROA indicates improved efficiency in utilizing company assets to generate profits. The higher return suggests stronger operational performance and effective resource allocation.
ROA Indicator
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
ROA Indicator
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Operating Margin (%) ★ Buffett's Key Metric
AstraZeneca's operating margin for the most recent quarter is 24.3%, compared to 27.0% in the previous quarter, with a long-term trend value of 15.5%. This decline in operating margin may indicate increased production or operational costs, pricing pressures, or lower revenue retention. A reduction in margin suggests that certain cost components are weighing on profitability, potentially requiring adjustments in expense management.
Operating Margin
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
Operating Margin
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Net Margin (%) ★ Buffett's Key Metric
Net margin for the most recent quarter is 16.9%, compared to 21.5% in the previous quarter, with a long-term trend value of 14.5%. This decline in net margin may indicate rising operational costs, pricing pressures, or changes in revenue mix that are affecting overall profitability. A lower net margin suggests that expenses have grown at a faster rate than revenue, potentially requiring adjustments in cost management or pricing strategy.
Net Margin
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
Net Margin
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🔴 Long-Term Debt & EBITDA
The current long-term debt is 24,714 million USD, and EBITDA is 4,897 million USD. The long-term debt to EBITDA ratio for the most recent quarter is 504.7%, compared to 538.4% in the previous quarter, with a long-term trend value of 600.1%. This decline in the long-term debt to EBITDA ratio suggests an improvement in the company's ability to manage and service its long-term debt obligations. The lower ratio indicates stronger financial flexibility, potentially driven by higher earnings generation or reduced leverage.
Long-Term Debt to EBITDA Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
Despite the decrease, the ratio remains above 400%, which may still indicate financial concerns that require careful monitoring. A declining trend in this ratio is typically a positive sign for investors, as it implies reduced financial risk and an improved capacity to meet long-term liabilities.
Long-Term Debt & EBITDA
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Long-Term Debt to EBITDA Ratio
Despite the decrease, the ratio remains above 400%, which may still indicate financial concerns that require careful monitoring. A declining trend in this ratio is typically a positive sign for investors, as it implies reduced financial risk and an improved capacity to meet long-term liabilities.
Long-Term Debt & EBITDA
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟢 Long-Term Debt & Assets
The current long-term debt is 24,714 million USD, and total assets are 112,422 million USD, resulting in a debt ratio of 22.0%. This decline in the long-term debt-to-assets ratio indicates an improvement in financial stability, as the company is reducing its reliance on long-term debt relative to its total assets. This suggests either an increase in total assets or a reduction in outstanding long-term liabilities.
Long-Term Debt to Assets Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
The current level remains within the safe range <40%, reflecting a strong balance sheet and a conservative debt structure. A declining debt-to-assets ratio is generally seen as a positive signal for investors, as it implies lower financial risk and greater balance sheet resilience.
Long-Term Debt & Assets
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Long-Term Debt to Assets Ratio
The current level remains within the safe range <40%, reflecting a strong balance sheet and a conservative debt structure. A declining debt-to-assets ratio is generally seen as a positive signal for investors, as it implies lower financial risk and greater balance sheet resilience.
Long-Term Debt & Assets
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Long-Term Debt & Equity ★ Buffett's Key Metric
The current long-term debt is 24,714 million USD, while Total Equity stands at 44,810 million USD, resulting in a debt-to-equity ratio of 55.2%. This decline in the long-term debt-to-equity ratio suggests improved financial strength, as the company is reducing its reliance on debt financing relative to its equity base. This may be the result of increased retained earnings, debt repayments, or higher equity financing, all of which contribute to a healthier balance sheet.
Long-Term Debt to Equity Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
Although the ratio has decreased, it is still within the healthy range 50%–150%, suggesting that debt levels remain manageable and in line with industry standards. A declining debt-to-equity ratio is generally a positive signal for investors, reflecting reduced leverage and improved financial flexibility.
Long-Term Debt & Equity
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Long-Term Debt to Equity Ratio
Although the ratio has decreased, it is still within the healthy range 50%–150%, suggesting that debt levels remain manageable and in line with industry standards. A declining debt-to-equity ratio is generally a positive signal for investors, reflecting reduced leverage and improved financial flexibility.
Long-Term Debt & Equity
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Equity to Assets
The current equity is 44,810 million USD, while total assets stand at 112,422 million USD, resulting in an equity-to-assets ratio of 39.9%. This increase in the equity-to-assets ratio indicates a strengthening financial position, as the company is relying more on its own capital rather than external debt. The rise suggests higher retained earnings, new equity issuance, or asset appreciation, all of which contribute to long-term financial stability.
Equity to Assets Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (%)
Although the ratio has increased, it is still within the monitoring range 40%–50%, suggesting that while financial leverage is moderate, continued assessment is recommended. A rising equity-to-assets ratio is generally a positive sign for investors, as it indicates lower financial risk and improved capital structure.
Equity & Assets
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Equity to Assets Ratio
Although the ratio has increased, it is still within the monitoring range 40%–50%, suggesting that while financial leverage is moderate, continued assessment is recommended. A rising equity-to-assets ratio is generally a positive sign for investors, as it indicates lower financial risk and improved capital structure.
Equity & Assets
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🔴 Quick Ratio
The quick ratio for AstraZeneca is 0.67, compared to 0.70 in the previous quarter, with a long-term trend value of 0.59. This decline in the quick ratio may indicate lower liquidity, reduced cash reserves, or an increase in short-term liabilities. The ratio has now fallen below 0.8, signalling potential liquidity concerns that may require adjustments in working capital management or access to additional short-term funding.
Quick Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports
Quick Ratio
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🔴 Current Ratio
The current ratio for AstraZeneca is 0.86, compared to 0.90 in the previous quarter, with a long-term trend value of 0.80. This decline in the current ratio may indicate a higher reliance on short-term liabilities, reduced cash flow, or increased working capital constraints. The ratio has now fallen below 1.0, signaling potential liquidity concerns. This suggests that the company may face difficulties meeting short-term obligations and might require improved cash flow management or additional financing.
Current Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports
Current Ratio
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🔴 Net Working Capital
The net working capital (NWC) for AstraZeneca in the most recent quarter is -4,597 million USD, compared to -2,990 million USD in the previous quarter, with a long-term trend value of 953 million USD.
Net Working Capital
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Net Working Capital
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🔴 Inventory Turnover Ratio
The inventory turnover ratio for AstraZeneca in the most recent quarter is 1.63, compared to 1.58 in the previous quarter. This increase in inventory turnover indicates that AstraZeneca is selling goods more rapidly, suggesting strong demand, efficient inventory management, and optimized supply chain processes. The turnover ratio has fallen below the 3.0, indicating low inventory turnover, which may result in excessive stockpiling, potential obsolescence, or weak demand. This situation requires closer monitoring to prevent liquidity constraints.
Inventory Turnover Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports
Inventory Turnover Ratio
🔴 Asset Turnover Ratio
The assets turnover ratio for AstraZeneca in the most recent quarter is 0.50, compared to 0.52 in the previous quarter. This decline in the assets turnover ratio may suggest lower revenue generation, excess assets, or inefficiencies in assets utilization. A decreasing trend could indicate weaker sales growth or an overinvestment in fixed assets. The ratio has fallen below the 1.0, suggesting that AstraZeneca may have a high level of assets relative to revenue generation. This could indicate underutilized resources or the need for improved asset efficiency.
Assets Turnover Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports
Assets Turnover Ratio
🔴 Book Value / Share
The book value per share (BVPS) is a key valuation metric that represents the equity value per outstanding share. Calculated by dividing total book value by the number of shares, it helps assess whether a stock trades above or below its book value.
Source: MarketVectors.Pro, AstraZeneca Financial Reports (USD)
Book Value per Share Valuation
Source: MarketVectors.Pro, AstraZeneca Financial Reports (USD, generated on 30 July 2025)
| Q2 24 | Q2 25 | Change (%) | |
| Book Value / Share | 12.69 | 14.37 | 13.24 % |
Book Value per Share Valuation
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟢 Graham Method
The intrinsic value of AstraZeneca’s stock is calculated using Benjamin Graham’s formula, which takes into account the current earnings per share (EPS) and an assumed growth rate (g), providing a simplified yet insightful perspective on a company’s value.
Benjamin Graham Valuation
Source: MarketVectors.Pro, AstraZeneca Financial Reports (USD, generated on 30 July 2025)
Benjamin Graham Valuation
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟢 Discounted Cash Flow ★ Buffett's Key Metric
The discounted cash flow (DCF) method is used to estimate AstraZeneca’s intrinsic value by projecting future cash flows and discounting them to their present value. This approach considers the company’s potential to generate cash flows in the future, taking into account the time value of money and associated risks.
The terminal value represents the value of AstraZeneca’s cash flows beyond the five-year forecast horizon. It is calculated using the Gordon Growth Model, assuming a perpetual growth rate of 4.0% and WACC of 7.9%. The calculated terminal value is 643,469 million USD.
Total Intrinsic Value Calculations
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Assuming 3,118 million shares outstanding, the intrinsic value per share is approximately 159.73 USD. The current market price of AstraZeneca’s stock is 75.63 USD. Discounted cash flow valuation indicates that the stock is 52.7% undervalued, trading below its intrinsic value.
Discounted Cash Flow Valuation
Source: MarketVectors.Pro, AstraZeneca Financial Reports (USD, generated on 30 July 2025)
| Value | |
| Present Value of FCFs | 58,067 |
| Present Value of Terminal Value | 439,967 |
| Total Intrinsic Value | 498,034 |
Discounted Cash Flow Valuation
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 Assets Correlation
The Pearson correlation analysis for AstraZeneca examines the relationship between share price and key financial indicators. Gross profit has a correlation of 0.75, which indicates a strong relationship, meaning profitability is a key driver of stock price movements. Operating income is correlated at 0.07, suggesting a weak relationship with share price fluctuations.
Source: MarketVectors.Pro, AstraZeneca Financial Reports
Current liabilities are correlated at 0.91, implying that short-term obligations are closely monitored by investors, influencing stock valuation. Total assets have a correlation of 0.92, confirming a strong relationship between asset growth and market performance.
Key Financial Indicators Growth Dynamics
Source: MarketVectors.Pro, AstraZeneca Financial Reports, Index=100 on Q4 10
| Pearson Correlation | |
| Share Price | 1 |
| Gross Profit | 0.75 |
| Operating Income | 0.07 |
| Current Liabilities | 0.91 |
| Total Assets | 0.92 |
Key Financial Indicators Growth Dynamics
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Premium Plan.
Download now with your Premium Plan.
🟡 FCF Margin Scenarios
• Optimistic Scenario: 19%, driven by operational efficiencies and cost optimisation.
• Base Case: 14% of revenue, consistent with historical trends.
• Pessimistic Scenario: 10%, reflecting higher operating and labour costs. Impact of Changes in FCF Margin
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
An approximately 5-percentage-point increase in the FCF margin to 19%, results in an additional 2,551 milion USD in FCF, highlighting the critical role of operational efficiency. Conversely, a decrease to 10% reduces FCF by 2,534 milion USD, illustrating the significant impact of profitability on cash flow generation.
Projected FCF Margin Scenarios Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
• Base Case: 14% of revenue, consistent with historical trends.
• Pessimistic Scenario: 10%, reflecting higher operating and labour costs. Impact of Changes in FCF Margin
| FCF Margin (%) | Revenue TTM | FCF TTM | Difference | |
| Optimistic | 19% | 56,501 | 10,735 | 2,551 |
| Base Case | 14% | 56,501 | 8,184 | – |
| Pessimistic | 10% | 56,501 | 5,650 | -2,534 |
Projected FCF Margin Scenarios Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
🟡 Operating Costs Scenarios
• Optimistic Scenario: 78%, reflecting enhanced efficiency and lower costs.
• Base Case: 80% of revenue, aligned with historical trends and cost structures.
• Pessimistic Scenario: 82%, driven by rising wages and increased energy costs. Impact of Changes in FCF Margin
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Reducing operational costs to 78% of revenue leads to a 1,106 milion USD increase in operating profit, emphasising the significance of cost control in enhancing margins. Increasing costs to 82% of revenue results in a 1,154 milion USD decline in operating profit, highlighting the sensitivity of profitability to rising expenses.
Projected Operating Costs Scenarios Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
• Base Case: 80% of revenue, aligned with historical trends and cost structures.
• Pessimistic Scenario: 82%, driven by rising wages and increased energy costs. Impact of Changes in FCF Margin
| Operating Costs (%) | Revenue TTM | Operating Profit | Difference | |
| Optimistic | 78% | 56,501 | 12,430 | 1,106 |
| Base Case | 80% | 56,501 | 11,324 | – |
| Pessimistic | 82% | 56,501 | 10,170 | -1,154 |
Projected Operating Costs Scenarios Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
🟡 Revenue Growth Scenarios
Optimistic Scenario: Projected to grow by 20% annually, driven by:
• Robust macroeconomic conditions.
• Strong industry growth with minimal disruptions.
• Favorable regulatory and competitive environment. Base Case: Projected to grow by 17% annually, driven by: • Stable macroeconomic conditions.
• Balanced market growth with manageable risks.
• Limited external disruptions from regulation or supply chains. Pessimistic Scenario: Projected to grow by 14% annually, driven by: • Global economic uncertainty and potential downturn.
• Increased competition and rising operational costs.
• Regulatory and supply chain challenges impacting business operations.
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD, TTM)
The projected revenue for the next twelve months varies depending on the scenario. Under the optimistic scenario, revenue is expected to increase by 20% to 68,071 million USD, reflecting strong market growth and operational efficiency. In the base case scenario, revenue is forecasted to grow by 17% to 66,143 million USD, assuming stable economic conditions and consistent business expansion. However, under the pessimistic scenario, revenue is projected to increase by 14% to 64,215 million USD, reflecting potential economic slowdowns or adverse market conditions.
Projected Revenues Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
The variation between projected scenarios highlights the AstraZeneca's ability to perform across a range of market conditions. The growth even in the pessimistic case reflects a degree of resilience and suggests a strong underlying business model. This outlook supports confidence in management’s ability to navigate uncertainty while sustaining forward momentum. Scenario analysis enhances strategic visibility, helping stakeholders understand the potential bandwidth of future results.
• Strong industry growth with minimal disruptions.
• Favorable regulatory and competitive environment. Base Case: Projected to grow by 17% annually, driven by: • Stable macroeconomic conditions.
• Balanced market growth with manageable risks.
• Limited external disruptions from regulation or supply chains. Pessimistic Scenario: Projected to grow by 14% annually, driven by: • Global economic uncertainty and potential downturn.
• Increased competition and rising operational costs.
• Regulatory and supply chain challenges impacting business operations.
| Revenue | Net Income | Revenue (Next) | Net Income (Next) | |
| Optimistic | 56,501 | 8,299 | 68,071 | 9,998 |
| Base Case | 56,501 | 8,299 | 66,143 | 9,715 |
| Pessimistic | 56,501 | 8,299 | 64,215 | 9,432 |
Projected Revenues Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
The variation between projected scenarios highlights the AstraZeneca's ability to perform across a range of market conditions. The growth even in the pessimistic case reflects a degree of resilience and suggests a strong underlying business model. This outlook supports confidence in management’s ability to navigate uncertainty while sustaining forward momentum. Scenario analysis enhances strategic visibility, helping stakeholders understand the potential bandwidth of future results.
🟡 Net Income Growth Scenarios
The projected net income for the next twelve months varies depending on the scenario. Under the optimistic scenario, net income is expected to increase by 20% to 9,998 million USD, reflecting improved profitability and strong financial performance. In the base case scenario, net income is forecasted to grow by 17% to 9,715 million USD, assuming stable market conditions and effective cost management. However, under the pessimistic scenario, net income is projected to increase by 14% to 9,432 million USD, reflecting potential challenges such as higher operational costs or slowing revenue growth.
Projected Net Income Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
The projected resilience in net income across all scenarios suggests a stable underlying profitability profile. Even under adverse assumptions, the AstraZeneca is expected to maintain earnings growth, indicating effective cost controls and strong core operations. This consistency can help support valuation multiples and reduce perceived investment risk. Scenario modeling enhances transparency and strengthens the credibility of financial forecasting in the eyes of stakeholders.
Projected Net Income Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
The projected resilience in net income across all scenarios suggests a stable underlying profitability profile. Even under adverse assumptions, the AstraZeneca is expected to maintain earnings growth, indicating effective cost controls and strong core operations. This consistency can help support valuation multiples and reduce perceived investment risk. Scenario modeling enhances transparency and strengthens the credibility of financial forecasting in the eyes of stakeholders.
🟡 Financial Performance Overview
AstraZeneca demonstrated stronger financial performance in the most recent period, reflecting strong revenue growth, operational efficiency, and profitability improvements revenue increased by 11.7% year-over-year, reaching 14,457 million USD, supported by strong sales performance across all key markets. At the same time, EBITDA grew by 21.7% year-over-year, totaling 4,897 million USD, reflecting increased operational costs and margin pressures.
Revenue & Net Income
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
Notably, net income surged by 27.1% year-over-year, reaching 2,450 million USD, negatively impacting AstraZeneca's net margin, which expanded to 16.9%. This growth reflects effective expense control and revenue expansion, strengthening the company’s bottom-line performance.
Revenue & Net Income
Notably, net income surged by 27.1% year-over-year, reaching 2,450 million USD, negatively impacting AstraZeneca's net margin, which expanded to 16.9%. This growth reflects effective expense control and revenue expansion, strengthening the company’s bottom-line performance.
Key Performance Indicators (KPIs)
Source: MarketVectors.Pro, AstraZeneca Financial Reports (YoY)
Valuation & Market Position
AstraZeneca’s valuation metrics indicate a strengthened financial standing. The EV to EBITDA (TTM) ratio currently stands at 15.25, decreasing from 16.65, reflecting a dual shift – rising operational performance and declining market valuation. This indicates a balanced valuation, with stable investor perception
EV to EBITDA Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (TTM)
The EV to EBITDA trendline illustrates AstraZeneca’s valuation trajectory, with a declining enterprise value despite improving earnings, possibly signaling undervaluation or market pessimism.
Source: MarketVectors.Pro, AstraZeneca Financial Reports (TTM)
Meanwhile, the P/E (Price to Earnings) ratio has declined to 26.1, down from 36.7 a year ago, potentially signaling a more balanced market outlook on AstraZeneca’s earnings potential. The P/S (Price to Sales) ratio has declined to 3.83, compared to 4.66 a year ago, suggesting a more conservative valuation stance among investors.
| Change (%) | |
| Revenue Growth | 11.7% |
| EBITDA Growth | 21.7% |
| Net Income Growth | 27.1% |
| Net Margin | 17.0% |
| EPS | 28.9% |
EV to EBITDA Ratio
The EV to EBITDA trendline illustrates AstraZeneca’s valuation trajectory, with a declining enterprise value despite improving earnings, possibly signaling undervaluation or market pessimism.
| Ratio (TTM) | |
| EV/EBITDA | 15.25 |
| P/E Ratio | 28.41 |
| P/S Ratio | 3.83 |
Cash Flow & Liquidity ★ Buffett's Key Metric
AstraZeneca is experiencing a weakened cash flow position, reflecting potential liquidity challenges. The decline in cash flow may indicate increased operational costs or reduced cash inflows, requiring closer financial monitoring and strategic adjustments.
• Free Cash Flow (FCF) – totaled 1,463 million USD, indicating a decline in available cash resources, requiring enhanced financial oversight.
• Net Operating Cash Flow – declined by 139.3% year-over-year, reaching 342 million USD, suggesting weaker cash inflows from operating activities.
• Long-term debt – increased by 7.8%, which may lead to higher financial leverage and increased interest obligations.
AstraZeneca’s ability to generate substantial cash flow while increasing debt reinforces its financial flexibility, though ongoing financial management is essential to sustain long-term growth and strategic investments.
Free Cash Flow
Source: MarketVectors.Pro, AstraZeneca Financial Reports (million USD)
AstraZeneca's financial performance in the most recent quarter shows that EBITDA reached 4,897 million USD, indicating a potential slowdown in operational profitability. The company's return on equity (ROE) is 18.5%, pointing to reduced return on shareholder capital and weaker financial performance. The long-term debt-to-equity ratio stands at 55.2%, indicating a more resilient balance sheet and lower financial risk. The quick ratio is 0.67, highlighting tightened liquidity conditions and the need for cautious cash management. The EV/EBITDA ratio is currently 15.25x, reflecting a balanced or attractive valuation level relative to earnings. Overall, AstraZeneca’s financial health remains strong, with consistent revenue expansion, cost efficiency improvements, and tightened liquidity conditions. Meanwhile, the P/E ratio is declining, while AstraZeneca’s long-term prospects remain positive.
Free Cash Flow
AstraZeneca's financial performance in the most recent quarter shows that EBITDA reached 4,897 million USD, indicating a potential slowdown in operational profitability. The company's return on equity (ROE) is 18.5%, pointing to reduced return on shareholder capital and weaker financial performance. The long-term debt-to-equity ratio stands at 55.2%, indicating a more resilient balance sheet and lower financial risk. The quick ratio is 0.67, highlighting tightened liquidity conditions and the need for cautious cash management. The EV/EBITDA ratio is currently 15.25x, reflecting a balanced or attractive valuation level relative to earnings. Overall, AstraZeneca’s financial health remains strong, with consistent revenue expansion, cost efficiency improvements, and tightened liquidity conditions. Meanwhile, the P/E ratio is declining, while AstraZeneca’s long-term prospects remain positive.
Disclaimer
This report is provided for informational purposes only and does not constitute financial, investment, legal, tax, or professional advice. The information, analyses, forecasts, and opinions contained herein are based on sources believed to be reliable as of the publication date. However, MarketVectors.Pro, its affiliates, officers, directors, employees, and agents make no warranties or representations, express or implied, regarding the accuracy, completeness, reliability, or suitability of this information for any particular purpose. The data, assumptions, and projections provided are subject to change without notice.
No Investment or Legal Advice
This report does not constitute an offer, recommendation, or solicitation to buy, sell, or hold any financial instrument, security, commodity, or investment. Any investment decisions made by the recipient are made entirely at their own discretion and risk. MarketVectors.Pro and its affiliates expressly disclaim any and all liability for investment losses, financial damages, or any other consequences arising from reliance on this report, whether such losses result from errors, omissions, misinterpretations, or unforeseen market conditions.
The recipient acknowledges and agrees that MarketVectors.Pro shall not be held liable under any legal theory, including but not limited to negligence, breach of fiduciary duty, or misrepresentation, for any direct, indirect, incidental, consequential, or punitive losses incurred. Furthermore, past performance is not indicative of future results, and no assurance or warranty is given regarding the accuracy, completeness, or reliability of the information contained herein. The recipient is strongly encouraged to seek independent professional advice before making any financial decisions.
This report may contain inaccuracies, errors, or omissions. MarketVectors.Pro and its affiliates expressly disclaim any responsibility for such inaccuracies and make no warranties, express or implied, regarding the correctness or completeness of the information provided. The recipient agrees not to hold MarketVectors.Pro liable for any such inaccuracies or their consequences.
Forward-Looking Statements and Risk Disclosures
This report may contain forward-looking statements based on assumptions, estimates, and expectations that are inherently subject to known and unknown risks and uncertainties. Actual results may differ materially from those projected due to factors beyond the control of MarketVectors.Pro, including but not limited to market fluctuations, geopolitical events, regulatory changes, and macroeconomic conditions. No assurances or guarantees can be made that any projections, expected returns, or forecasts will be realized.
Past performance is not indicative of future results. The recipient acknowledges that all forward-looking statements are inherently uncertain and that actual results may differ significantly from projections. MarketVectors.Pro does not guarantee any level of performance or return on investment.
Jurisdictional and Regulatory Considerations
This document is intended for recipients in jurisdictions where its distribution and access are legally permitted. It may not comply with regulatory standards in all jurisdictions and should not be used or relied upon in any jurisdiction where such distribution would violate local laws or regulations. Recipients are responsible for ensuring compliance with applicable local laws before engaging in any financial activities based on this report.
Confidentiality and Restriction on Distribution
This report is confidential and solely intended for the designated recipient. It may not be copied, reproduced, distributed, or shared without the prior written consent of MarketVectors.Pro. Unauthorized use or distribution of this document may be subject to legal action under applicable intellectual property and confidentiality laws.
Limitation of Liability
To the fullest extent permitted by law, MarketVectors.Pro, its affiliates, officers, directors, employees, and representatives expressly disclaim any and all liability for any damages or losses, whether direct, indirect, incidental, consequential, punitive, or otherwise, arising from the use or reliance on this report.
By accessing or using this report, the recipient acknowledges and agrees to the above terms and waives any claims against MarketVectors.Pro and its affiliates related to the content, analysis, or recommendations provided.
